Alkermes Plc (ALKS) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Total Cash From Operating Activities Chart for Alkermes Plc
Alkermes Plc (ALKS) operating cash flow for FY2025 was USD 520.8M, a 18.6% change from FY2024. Alkermes Plc's operating cash flow moved from USD -45.2M in 1991 to USD 520.8M in 2025 over 34 years. Operating cash flow compound annual growth rate: 5-year CAGR of 44.4%, 20-year CAGR of 7.8%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $6.92B
- Implied Share Price
- $41.22
- Enterprise Value
- $7.98B
- Revenue (TTM)
- $1.67B
- EBITDA
- $284.93M
- Profit Margin
- 3.97%
- Trailing P/E
- 108.47
- Forward P/E
- 133.33
- Price/Book (MRQ)
- 3.91
- Price/Sales (TTM)
- 4.15
- EV/EBITDA
- 36.62
- EV/Revenue
- 4.79
- Dividend Yield
- —
- Book Value
- $10.79
- Free Cash Flow (FY2025)
- $480.33M
- Free Cash Flow Yield
- 6.95%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.